Principles of soft tissue augmentation for the aging face by Burgess, Cheryl M
Clinical Interventions in Aging 2006:1(4) 349–355
© 2006 Dove Medical Press Limited. All rights reserved
349
REVIEW
Principles of soft tissue augmentation
for the aging face
Cheryl M Burgess
Center for Dermatology 
and Dermatologic Surgery, 
2311 M Street, Northwest, 
Suite 504, Washington, D.C. 
20037, USA
Correspondence: Cheryl M Burgess
Center for Dermatology and
Dermatologic Surgery, 2311 M Street, 
Northwest, Suite 504, Washington, D.C. 
20037, USA 
Tel +1 202 955 5757
Fax +1 202 955 5797
Email 
cheryl.burgess@ctr4dermatology.com
Abstract: In the quest for the “ideal” soft tissue ﬁ  ller, many diverse products have been 
developed. The expanding market of available ﬁ  llers is a testament that no one product will 
ideally suit all patients or clinicians. In addition, the challenge of satisfying the criteria of an 
ideal ﬁ  ller has driven researchers to take a variety of development paths. This has resulted in 
multiple categories to characterize soft tissue ﬁ  llers. These ﬁ  llers are categorized according to: 
(1) ﬁ  ller material, eg, autologous, natural, synthetic; (2) mechanism of action, eg, void ﬁ  ller, 
neocollagenesis, ﬁ  broblast stimulation; (3) patient type and proﬁ  le, eg, younger versus older 
patient, rhytids versus “sinking and sagging” skin; or (4) durability of treatment effects, eg, 
temporary, semi-permanent, or permanent. Although strategies for soft tissue augmentation may 
be quite diverse, strategies should share a universal goal to address fat redistribution (atrophy 
and hypertrophy), the primary underlying morphological cause of facial aging. To accomplish 
this, volumizers are now available that are injected more deeply, resulting in the restoration of 
supportive structure and foundation. These can be used in combination with other products that 
are used more superﬁ  cially for smoothing skin surfaces. As numerous soft tissue ﬁ  llers enter 
the market, mechanisms and injection techniques become more divergent, and therefore require 
that the dermatologist and cosmetic surgeon receive adequate training to use products safely and 
effectively. This manuscript provides an overview of soft tissue ﬁ  llers and their proper use.
Keywords: soft tissue augmentation, ﬁ  llers, fat atrophy hypertrophy, highly active anti-retroviral 
therapy, lipoatrophy
Introduction
The quest for ideal ﬁ  llers for soft tissue augmentation has resulted in the development 
of many diverse products with divergent augmentation strategies and mechanisms of 
action. This is partially a testament to the fact that no one product will ideally suit the 
desires of all patients and all clinicians. Moreover, the formidable biological and aesthetic 
criteria of “the ideal ﬁ  ller” have driven researchers to take a variety of development 
paths. This has led to the development of multiple categories of soft tissue ﬁ  llers that 
are shown in Tables 1 and 2. 
The primary actions of these products are to occupy physical space, to induce 
collagen formation, and/or increase volume. Soft tissue ﬁ  llers are commonly categorized 
by durability. Both clinicians and patients have different preferences for durability. 
Convenience drives the use of more durable (semi-permanent and permanent) soft tissue 
ﬁ  llers or implants, because these products require fewer or no follow-up treatments. 
However, because the face continues to age following procedures, temporary or 
semi-permanent effects may be preferred, so the face can be periodically augmented 
to accommodate ongoing morphological changes. Some clinicians have also voiced 
concerns about the potential for long-term complications that may arise after treating 
with permanent soft tissue ﬁ  llers.
In general, soft tissue augmentation techniques have evolved from an early focus 
on the treatment of lines to, more recently, focusing on the treatment of facial areas. Clinical Interventions in Aging 2006:1(4) 350
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In addition, earlier methods focused on injection techniques 
that treated the superﬁ  cial levels of the skin. More recently, 
methods have progressed to injecting soft tissue ﬁ  llers into 
deeper regions. Another important development in the science 
of soft tissue augmentation is the growing acknowledgment 
of the fundamental morphological changes in the aging face 
that cause the outward appearance of aging. 
The culprit, generally implicated for the appearance of 
the aging face, is gravity. However, gravity is not the primary 
underlying cause of facial signs of aging. Rather, one of the 
primary causes of the aging face is the redistribution of fat 
(Donofrio 2000). The other causes of the aging face include 
environmental factors, dermal thinning, bone resorption 
(Vleggaar and Bauer 2004), and the loss of elasticity and 
collagen in the skin. Rhytids and wrinkles, caused by facial 
expressions, also contribute to the aging face. However, we 
now know that lines, caused by the underlying facial muscle 
contractions, respond best to botulinum toxin A, as opposed 
to using soft tissue ﬁ  llers to ﬁ  ll in the lines and creases. 
(Burgess 2005).
The atrophy/hypertrophy 
model for aging
In the young face, superﬁ  cial and deep fat is distributed 
evenly, creating a homogenous topographical appearance 
with smooth primary arcs and convexities. With intrinsic 
aging, the distribution of fat becomes altered. Fat atrophy 
and hypertrophy cause hills and valleys to develop, and 
produce demarcations between the cosmetic units. Fat 
atrophy begins to become clinically apparent in the temple 
and cheek and is followed by fat loss around the chin and 
mandibular areas. Features become concave, characterized by 
ﬂ  at lips, sunken temple and cheek, scalloped mandible, and 
increased shadowing among the resulting hills and valleys. 
With aging, the most signiﬁ  cant change in appearance is the 
sagging of excess skin caused by the conversion of primary 
arcs to straight lines. When evaluating the tendencies of 
facial skin vectors, the skin drapes inferiorly and diagonally 
from the temporal area towards the perioral region, thus 
Table 2 Soft tissue ﬁ  llers categorized by durability 
Temporary ﬁ  llers
  Fat transfer
  Fat autograft muscle injection
  Dermis and extracellular matrix
  Acellular allogeneic dermis
  Injectable microparticulate acellular allogeneic dermis
  Lyophilized human particulate fascia lata
  Bovine dermal collagen
  Bovine collagen cross-linked with glutaraldehyde
  Human-based collagen isolated from human ﬁ  broblast tissue cultures
  Human-based collagen cross-linked with glutaraldehyde
  Nonanimal stabilized hyaluronic acid derived from bacterial 
biofermentation process
  Viscoelastic nonanimal hyaluronic acid gel
  Viscoelastic acid gel from rooster combs
  Poly-L-lactic acid
Semi-permanent ﬁ  llers
  Synthetic calcium hydroxylapatite microspheres suspended in 
polysaccharide gel
  Expanded polytetraﬂ  uoroethylene
  Dual-porosity expanded polytetraﬂ  uoroethylene
  Alkyl-imide gel polymer
Permanent ﬁ  llers
  Silicone oil
  Polymethyl-methacrylate microspheres in denatured bovine collagen
Table 1 Soft tissue ﬁ  llers categorized by material
Natural implants
Autologous materials
  Fat  transfer
   Fat autograft muscle injection
  Cultured  human  ﬁ  broblasts
Cadaver-derived materials
   Dermis and extracellular matrix
   Acellular allogeneic dermis
   Injectable microparticulate acellular allogeneic dermis
   Lyophilized human particulate fascia lata
Collagen
  Bovine-derived  collagen
   Human-derived collagen from tissue culture
Hyaluronic acid
   Hyaluronic acid derived from rooster combs
   Nonanimal stabilized hyaluronic acid from bacterial fermentation
   Viscoelastic nonanimal hyaluronic acid derived from bacterial fermen-
tation
Synthetic or pseudo-synthetic implants
   Silicone oil
   Expanded polytetraﬂ  uoroethylene
   Dual-porosity expanded polytetraﬂ  uoroethylene
   Polymethylmethacrylate microspheres in denatured bovine collagen
   Poly-L-lactic acid
   Synthetic calcium hydroxylapatite microspheres suspended in aqueous 
polysaccharide gel
   Alkyl-imide gel polymerClinical Interventions in Aging 2006:1(4) 351
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creating a central focus on the perioral and mandibular 
regions. Intrinsic aging is characterized by fat atrophy in the 
periorbital, forehead, buccal, temporal, and perioral areas. 
Fat atrophy results from the collective effects of decreased 
fat cell size, diminished fat cell function, impaired fat cell 
differentiation, and redistribution of fat cells. Fat hypertrophy 
occurs submentally, in the jowl, lateral nasolabial fold, lateral 
labiomental crease, and lateral malar areas. The accumulation 
of fat pulls the encumbered skin downward under the force 
of gravity. In contrast, the loss of fat leaves excessive skin 
in proportion to the diminished volume, causing the excess 
skin to sag (Alster et al 2004; Donofrio 2004). 
Reversing the effects of fat atrophy/hypertrophy cannot 
be adequately accomplished through conservative techniques. 
A comprehensive approach that considers the entire face and 
all the underlying causes of aging is necessary. Volume must 
be restored in regions experiencing fat atrophy and excess fat 
must be removed from regions where fat has accumulated. 
Correcting the distribution of volume throughout the 
face can help restore homogenous topography, eliminate 
demarcations between cosmetic units, and restore the primary 
arcs (Donofrio 2004).
The atrophy/hypertrophy model for aging represents a 
shift from focusing on wrinkles and gravitational sagging to a 
more comprehensive approach that treats the aging face from 
“the inside out.” As stated earlier, acquiring the “ideal soft 
tissue ﬁ  ller” is hopeless, since preferences of patients and 
clinicians are not universal. However, the goal of soft tissue 
augmentation should involve a universal acknowledgment 
of the fundamental causes of the aging face. Products and 
treatment protocols can be tailored to the individual needs 
of the patient. 
Chronological age is among a variety of factors that may 
inﬂ  uence the choice of soft tissue ﬁ  ller(s). In general, older 
patients are likely to require soft tissue ﬁ  llers that primarily 
produce volume and correct the results of fat atrophy by 
re-creating the foundation and underlying structure of the 
face. Younger patients are more likely to require soft tissue 
fillers that smooth surfaces, such as creases and folds. 
In younger patients, the typical goal of lip augmentation 
is to make lips appear bigger and fuller, whereas in older 
patients the goal is to restore volume to lips that has been 
lost through fat atrophy. 
Ethnicity is another signiﬁ  cant determinant used to match 
soft tissue ﬁ  llers with the speciﬁ  c needs of the patient. Based 
on the particular ethnic skin-type, some soft tissue ﬁ  llers will 
achieve better results than others will. For example, volumiz-
ers are generally more effective in ethnic skin, due to the 
presence of sagging skin. Histologically, there is less thinning 
of collagen bundles and elastic tissue in this skin-type. The 
treatment of ethnic skin does not involve correcting the 
typical photodamage that occurs in Caucasian skin, such as 
creases and surface lines.
For soft tissue augmentation, a variety of products 
exists, and new products are continually entering the 
market. These soft tissue ﬁ  llers provide correction by two 
basic mechanisms: (1) the ﬁ  ller material occupies a void 
space, or (2) the ﬁ  ller material stimulates processes that 
produce volume. An overview of historical developments 
in the science of soft tissue augmentation is presented here, 
including a discussion of current products, patient selection, 
and injection techniques.
Soft tissue ﬁ  llers
Early emergence of ﬁ  llers (fat, parafﬁ  n)
Groundbreaking work in the science of soft tissue ﬁ  llers 
began in the late 1800s after Neuber reported using blocks 
of free fat, harvested from the arms to reconstruct depressed 
facial defects. Only a few years later, Gersuny became the 
ﬁ  rst to use the injection technique for cosmetic correction; 
the injected substance was parafﬁ  n. In 1911, injection of 
autologous fat into the subcutaneous space was reported by 
Bruning. However, advances in the use of autologous fat 
were tempered by the limited efﬁ  cacy of fat injection, since 
transplants lost 50% of their volume after only one year (Klein 
and Elson 2000). This drove researchers to continue pursuit 
of more ideal ﬁ  llers.
Today, autologous fat transfer remains a popular 
procedure because there is no risk of rejection and no 
cost for materials. Recent advances in fat transfer include 
suspending the autologous fat in the patient’s plasma, 
which increases the longevity of the procedure. Autologous 
fat is injected into subcutaneous fat layer and/or muscle. 
Overcorrection and repeated treatment sessions are often 
necessary. The treatment lasts from several months to 
several years, depending on technique and transplant 
preparation (Burgess 2005).
Emergence of collagen
and hyaluronic acid
Collagen is a ﬁ  brous protein found in both humans and 
animals. In soft tissue augmentation, collagen preparations 
are used to ﬁ  ll in voids. Development of bovine collagen for 
soft tissue augmentation began in the 1950s with the work of 
Gross and Kirk, who were the ﬁ  rst to successfully prepare a Clinical Interventions in Aging 2006:1(4) 352
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bovine collagen gel. However, in the 1960s, the use of bovine 
collagen received a signiﬁ  cant boost from the development 
of a process that reduced the antigenicity by removing the 
nonhelical amino and carboxy terminal telopeptides. This led 
the way to the development of a clinically useful preparation 
of bovine collagen. In 1981, Zyderm® I Collagen Implant 
(INAMED Aesthetics, CA, USA) received approval from 
the Food and Drug Administration (FDA) and quickly 
became a popular ﬁ  ller for soft tissue augmentation (Klein 
and Elson 2000). Preparations are available with either low 
or high concentrations of cross-linking. These ﬁ  llers are 
injected intradermally into the superﬁ  cial papillary dermis 
of the nasolabial folds (Klein 1989). They usually require 
overcorrection due to resorption of water from the preparation, 
which occurs within 24 h (Cheng et al 2002).
Further developments led to a more durable bovine 
collagen ﬁ  ller that retains its integrity and inherent water 
content to a greater degree because of cross-linking with 
glutaraldehyde. Cross-linking strengthens the collagen and 
makes it more resistant to proteolytic degradation (Elson 
1999). Bovine collagen cross-linked glutaraldehyde is injected 
into the mid-reticular or deep reticular dermis at the dermal 
subcutaneous interface (Cheng et al 2002). Unlike collagen 
ﬁ  llers with low concentrations of cross-linking, Zyplast does 
not require overcorrection.
Human-based collagen is available in two forms: (1) 
isolated from human ﬁ  broblasts cell cultures, and (2) cross-
linked with glutaraldehyde. CosmoDerm® (INAMED 
Aesthetics, CA, USA) is an example of highly puriﬁ  ed human-
based collagen, available in two different concentrations. 
CosmoPlast® (INAMED Aesthetics, CA, USA) is an example 
of human-based collagen cross-linked with glutaraldehyde. 
Both human collagens are FDA-approved for rhytids and 
scars. CosmoDerm is used more superﬁ  cially (Bisaccia and 
Scarborough 1992), whereas CosmoPlast is reserved for 
deeper lines and is used off-label for the lips. Corrections 
using collagen-based ﬁ  llers last from several weeks to several 
months (Glogau et al 2004).
Hyaluronic acid is a naturally occurring polysaccharide, 
a glycosaminoglycan that is a component of the “ground 
substance” or extracellular matrix of the dermis (Lupton 
and Alster 2000). Hyaluronic acid provides volume to the 
skin, shape to the eyes, and is chemically identical across all 
species and all tissue types (Larsen et al 1993). It has natural 
hydrating functions that form the basis of its role in soft tissue 
augmentation (Lupton and Alster 2000). Fillers containing 
hyaluronic acid are true ﬁ  llers, in which the mechanism of 
augmentation is simply to ﬁ  ll space. There are two sources 
of hyaluronic acid used for soft tissue augmentation: (1) 
nonanimal stabilized hyaluronic acid (NASHA) produced 
from a bacterial biofermentation process (eg, Restylane®, 
Medicis Aesthetics, AZ, USA; and Juvederm®, INAMED 
Aesthetics, CA, USA), and (2) animal-derived hyaluronic 
acid puriﬁ  ed from rooster combs (eg, Hylaform®, INAMED 
Aesthetics, CA, USA) (Burgess 2005). Hyaluronic acid is readily 
broken down in the dermis and eliminated via the lymphatics 
and the liver (Klein and Elson 2000). However, cross-linking 
with ester and ether linkages stabilizes the molecule for greater 
durability in dermal processes (Burgess 2005). 
Bacterial-derived hyaluronic acid is available in 
different concentrations. Depending on the concentration, 
it can be injected into either the (1) reticular dermis and/or 
subcutaneous-dermal plane, or (2) papillary dermis. Various 
injection techniques apply and should not be overcorrected 
(Lowe et al 2001).
Viscoelastic hyaluronic acid is also available. Viscoelastic 
nonanimal hyaluronic acid gel (eg, Juvederm) is available 
in three different concentrations. It is intended for injection, 
based on concentration, into either: (1) the superﬁ  cial dermis, 
(2) the mid dermis, or (3) the mid to deep dermis. Hyaluronic 
acid derived from rooster combs (eg, Hylaform) is available 
in a 5.5 mg/ml concentration with a particle size of 500 μm, 
and 20% cross-linking as a result of glutaraldehyde and vinyl 
sulfone stabilization (Burgess 2005). Hylaform is indicated 
for injection into the mid-to-deep dermis. It can be used in 
younger patients for shaping and volumizing in addition to 
restoring lost lip structure in older patients. All hyaluronic 
acid ﬁ  llers can be used in the body of the lips to reshape or 
enlarge the lips. However, collagen ﬁ  llers are reserved for 
use in the vermillion border. Fillers containing hyaluronic 
acid are generally considered to last twice as long as ﬁ  llers 
containing collagen. Both collagen and hyaluronic acid are 
indicated for the treatment of more superﬁ  cial corrections, 
such as smoothing surfaces, as opposed to ﬁ  llers used in 
deeper regions to create more supportive structure and 
foundation. Theoretically, hyaluronic acid can be used 
to volumize. However, this application is considered 
cost-prohibitive.
Recent developments
in soft tissue ﬁ  llers
Poly-L-lactic acid (PLA) (Sculptra®, Sanoﬁ  -Aventis, NJ, USA) 
is a biodegradable bioabsorbable synthetic polymer that has Clinical Interventions in Aging 2006:1(4) 353
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been used for several decades in resorbable medical devices, 
such as sutures, surgical sealant meshes, screws, plates, and 
membranes for guided tissue regeneration (Vleggaar and 
Bauer 2004; Burgess and Quiroga 2005). In soft tissue 
augmentation, PLA is used exclusively to produce volume 
in areas of “sinking and sagging” skin. It is not intended for 
the focused treatment of speciﬁ  c wrinkles, as is the case with 
most traditional soft tissue ﬁ  llers. Rather, PLA is intended 
for the treatment of areas requiring contouring or sculpting. 
Although other volumizers can be used to treat facial areas, 
this can be quite costly. In many patients, PLA can also be 
used in combination with other soft tissue ﬁ  llers for a variety 
of applications in soft tissue augmentation.
Poly-L-lactic acid was recently approved in the US for 
the treatment of facial lipoatrophy in patients with human 
immunodeﬁ  ciency virus (HIV). Moreover, it has been used 
since 1999 in more than 30 other countries to treat a variety 
of facial volume and contour deﬁ  ciencies (Vleggaar and 
Bauer 2004).
Facial lipoatrophy occurs in healthy adults from the 
natural course of aging. Facial lipoatrophy may also occur 
as a result of surgical procedures to cause extensive weight 
loss. It can also be manifested by speciﬁ  c disease states, 
either inherited or acquired, in which lipodystrophy results in 
metabolic disturbances that lead to abnormalities in adipose 
tissue. In addition to disease states, facial lipoatrophy also 
results from the treatment of certain diseases, such as the use 
of anti-retroviral therapy to treat HIV. In particular, facial 
lipoatrophy has been associated to a large degree with the 
use of protease inhibitors, and to a lesser degree with the 
use of nucleoside reverse transcriptase inhibitors, as part of 
highly active anti-retroviral therapy for treatment of HIV 
(Ascher et al 2006). Facial lipoatrophy has been treated 
using silicone oil, bovine collagen, particulate human fascia 
lata, and autologous fat. (James et al 2002). Safety and 
efﬁ  cacy of PLA for treatment of facial lipoatrophy has been 
demonstrated in several studies with immunocompromised 
patients (Valantin et al 2003; Moyle et al 2004; Onesti et al 
2004; Mest 2005). 
For example, Burgess and Quiroga (2005) used PLA 
to treat lipoatrophy in 61 HIV-infected patients over a 
5-month period. The amount of PLA varied from 1–4 vials, 
depending on the degree of lipoatrophy severity and areas of 
involvement. The number of treatment sessions also varied. 
Mild cases required 1–2 treatment sessions; moderate cases, 
approximately 4 treatment sessions; and severe lipoatrophy 
required 4 or more treatment sessions. The amount of PLA 
was gradually decreased over subsequent sessions. All 
patients experienced signiﬁ  cant clinical improvement, defined 
as smoothing of the skin with decreased concavities or 
depressions, and improved overall appearance. The effect 
was long lasting, remaining for up to 30 months in patients, 
depending on initiation of treatment and length of follow-up 
(Burgess and Quiroga 2005). At the time of writing, there 
have been no reported adverse events. In addition to treating 
HIV-infected patients, significant experience has also 
accumulated in the treatment of immunocompetent patients 
for cosmetic reasons (Vleggaar and Bauer 2004).
Poly-L-lactic acid is distinct from other soft tissue ﬁ  llers, 
due to its mechanism of action, treatment plan, preparation of 
injection material, and injection technique (Burgess and Lowe 
2006). The application of PLA in soft tissue augmentation 
exploits a mechanism of action not seen in any other soft tissue 
ﬁ  ller. Although the injection of PLA causes an immediate 
effect by physically occupying space, this initial response is 
temporary and only lasts one week or less (Mest 2005). Once 
the carrier solution is absorbed, a delayed but progressive 
volumizing effect begins. The process of hydration, loss 
of cohesion and molecular weight, and solubilization and 
phagocytosis of PLA by the host’s macrophages, slowly 
degrades PLA into lactic acid microspheres and eliminates 
CO2 by way of respiratory excretion. Crystals are left behind 
to stimulate collagen and a granulomatous reaction. This 
inﬂ  ammatory reaction elicits resorption and the formation 
of ﬁ  brous connective tissue about the foreign body, causing 
dermal ﬁ  broplasia that leads to the desired cosmetic effect 
(Burgess and Quiroga 2004). 
Poly-L-lactic acid is injected into deeper regions for 
creating supportive structure and foundation. In addition, it 
can be used to build up the maxillary fat pads. Poly-L-lactic 
acid cannot be injected into the lips. Effects of volume 
restoration can persist for as long as 18–24 months, but are 
not permanent (Burgess and Quiroga 2005; Mest 2005). 
Beljaards and colleagues (2005) has reported the late onset 
of granulomatous skin reactions in three immunocompetent 
patients receiving PLA treatment. The report underscores 
necessity for dermatologists to recognize and acknowledge 
the distinct differences between PLA and other soft tissue 
fillers. The characteristics that distinguish PLA from 
traditional ﬁ  llers are: (1) the mechanism of action, (2) the 
treatment plan, (3) the preparation of the injection material, 
and (4) the injection technique (Burgess and Lowe 2006).
Poly-L-lactic acid causes a gradual volume restoration 
that may take 3–6 months to develop. In addition, the rate of Clinical Interventions in Aging 2006:1(4) 354
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dermal thickening increases from the ﬁ  rst to last injection. 
Since immediate correction is not the primary goal, as is 
the case in most traditional ﬁ  llers, the use of PLA requires a 
markedly different approach and treatment plan. Physicians 
should treat, wait, assess, and then decide how to proceed. 
Unlike other cosmetic injectables, PLA requires reconstitution 
before use. Although manufacturers recommend diluting 
in 3–5 mL of sterile water, 5–7 mL of sterile water is the 
customary reconstitution volume in the US. What is most 
critical for successful outcomes is that physicians receive 
sufﬁ  cient training before attempting to inject PLA. This 
training should include distinctions in injection technique. 
For example, as opposed to treating a speciﬁ  c line, the 
strategy of PLA treatment is to return volume to a facial area. 
In addition, PLA is injected into the dermal–subcutaneous 
plane, unlike collagen or hyaluronic acids. Finally, it is 
important that PLA injection be accompanied by massage of 
the treatment area and continued by the patient post-treatment 
(Werschler 2005).
At the Center for Dermatology and Dermatologic Surgery 
(Washington D.C., US), PLA has been successfully used to 
treat lipoatrophy of the hands, feet, face, and buttocks in both 
immunocompetent and immunocompromised patients. In 
addition, PLA has been used effectively in both the younger 
and older patient. However, in the older or aging patient, 
the thickness of the dermis plane is diminished, leading to 
a greater likelihood for bruising that results from increased 
fragility of blood vessels. In these patients, it is recommended 
that clinicians allow 8 weeks between treatment sessions, as 
opposed to the regular 4–6 week waiting period. For clinicians, 
the learning curve is longer in these patients, due to the 
concerns associated with treating patients with a thin dermis 
plane (Burgess 2006).
Conclusion
The growing marketplace of available soft tissue fillers is 
a testament to the necessity for individualized treatment to 
suit the individual desires of the patient and clinician. The 
fact that fillers provide augmentation through a variety of 
divergent mechanisms of action is also reﬂ  ective of the great 
challenges of developing an effective filler. The attributes 
and use of one particular filler are not exclusive to the use 
of another filler. However, not all fillers are appropriate 
for various indications and successful treatment depends 
on tailoring appropriate fillers to the desired outcome. For 
example, PLA cannot be injected into the lips, whereas 
collagen and hyaluronic acid are well suited for injection 
into the lips. To accommodate the patient’s individual 
needs, soft tissue fillers can be used either individually or 
combined, depending on treatment goals.
Soft tissue fillers may be more effective when used 
within a comprehensive strategy that addresses the underlying 
morphological causes that produce facial signs of aging. 
Although the aging face is a result of a number of processes, 
the primary cause of the aging face is the redistribution of fat 
and facial muscular activity. Fat atrophy and fat hypertrophy 
cause the development of hills and valleys, demarcation of 
cosmetic units, and disruptions of the primary arcs in the face. 
Therefore, strategies to restore the youthful appearance of the 
face should address these changes in a comprehensive manner. 
This represents a signiﬁ  cant shift from merely treating lines to 
treating entire areas of the face. This can be accomplished by 
using volumizers that are interjected more deeply, alone, or in 
combination with products that are injected more superﬁ  cially. 
However, as the marketplace of soft tissue ﬁ  llers continues 
to grow, techniques become more divergent, and therefore, 
requirements for adequate training on specific products 
becomes increasingly crucial. 
The potential of soft tissue augmentation continues to 
grow in step with increasing demand. Today, new clinical 
applications are gaining interest, such as the use of soft 
tissue ﬁ  llers in the treatment of nonfacial areas. Moreover, 
an increasing number of clinical trials are underway to assess 
the effectiveness of these new clinical applications. For 
the dermatologist and cosmetic surgeon, this represents an 
exciting, but challenging era.
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